Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 Over Twelve Years in a Consecutive Clinical Cohort

Anja Hviid Simonsen; Christian Sandøe Musaeus; Gitte Lund Christensen; Steen Gregers Hasselbalch; Gunhild Waldemar

doi:10.3233/JAD-201506

Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 Over Twelve Years in a Consecutive Clinical Cohort

Anja Hviid Simonsen, Christian Sandøe Musaeus, Gitte Lund Christensen, Steen Gregers Hasselbalch, Gunhild Waldemar

Abstract

Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.

Original language	English
Journal	Journal of Alzheimer's Disease
Volume	81
Issue number	4
Pages (from-to)	1369-1373
Number of pages	5
ISSN	1387-2877
DOIs	https://doi.org/10.3233/JAD-201506
Publication status	Published - 2021

Keywords

Aged
Aged, 80 and over
Alzheimer Disease/cerebrospinal fluid
Amyloid beta-Peptides/cerebrospinal fluid
Biomarkers/cerebrospinal fluid
Female
Humans
Male
Middle Aged
Peptide Fragments/cerebrospinal fluid
Phosphorylation
tau Proteins/cerebrospinal fluid

Access to Document

10.3233/JAD-201506

Cite this

@article{0ab56fa707b04fce90b03038192330de,

title = "Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 Over Twelve Years in a Consecutive Clinical Cohort",

abstract = "Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.",

keywords = "Aged, Aged, 80 and over, Alzheimer Disease/cerebrospinal fluid, Amyloid beta-Peptides/cerebrospinal fluid, Biomarkers/cerebrospinal fluid, Female, Humans, Male, Middle Aged, Peptide Fragments/cerebrospinal fluid, Phosphorylation, tau Proteins/cerebrospinal fluid",

author = "Simonsen, {Anja Hviid} and Musaeus, {Christian Sand{\o}e} and Christensen, {Gitte Lund} and Hasselbalch, {Steen Gregers} and Gunhild Waldemar",

year = "2021",

doi = "10.3233/JAD-201506",

language = "English",

volume = "81",

pages = "1369--1373",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "I O S Press",

number = "4",

}

TY - JOUR

T1 - Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 Over Twelve Years in a Consecutive Clinical Cohort

AU - Simonsen, Anja Hviid

AU - Musaeus, Christian Sandøe

AU - Christensen, Gitte Lund

AU - Hasselbalch, Steen Gregers

AU - Waldemar, Gunhild

PY - 2021

Y1 - 2021

N2 - Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.

AB - Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.

KW - Aged

KW - Aged, 80 and over

KW - Alzheimer Disease/cerebrospinal fluid

KW - Amyloid beta-Peptides/cerebrospinal fluid

KW - Biomarkers/cerebrospinal fluid

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Peptide Fragments/cerebrospinal fluid

KW - Phosphorylation

KW - tau Proteins/cerebrospinal fluid

UR - http://www.scopus.com/inward/record.url?scp=85108234882&partnerID=8YFLogxK

U2 - 10.3233/JAD-201506

DO - 10.3233/JAD-201506

M3 - Journal article

C2 - 33935081

SN - 1387-2877

VL - 81

SP - 1369

EP - 1373

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

IS - 4

ER -

Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 Over Twelve Years in a Consecutive Clinical Cohort

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this